Monthly Archives: January 2015

The Many Lives of Levodopa

The start of 2015 has been noteworthy for those with Parkinson’s disease (PD) as two new therapies  – Rytary™ and Duopa™ – were approved by the FDA at the start of January. Both therapies are updates to the gold-standard treatment of carbidopa/levodopa for those with PD. Manufacturers of both therapies hope to have the medications available on pharmacy shelves in the next few months. Yes, carbidopa/levodopa first came into use around 1970. However, these new therapies address a real need that current carbidopa/levodopa or Sinemet cannot meet … and that is good news. PDF has covered what Rytary and Duopa are (check out my… read more Read More

Science Summary from SfN 2014

When 30,000 neuroscientists gather together to talk about the brain, what can we learn about Parkinson’s disease? Our team found out at the latest meeting of the Society for Neuroscience (SfN) meeting in Washington, DC, which took place in November. At the meeting, PDF’s James Beck, Ph.D., VP for Scientific Affairs, and Beth Vernaleo, Ph.D., Senior Manager, Research Programs, were joined by PDF Research Advocates Todd Hebb and Paul Zimmet, D.D.S., both of whom live with PD. (Drs. Zimmet and Vernaleo are pictured inset).